These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 28786691

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Oct 25; 62(RR-09):1-12. PubMed ID: 24157696
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K, Cox H, Esmail A, Wasserman S, Chang KC, Lange C.
    Respirology; 2018 Jan 25; 23(1):36-45. PubMed ID: 28850767
    [Abstract] [Full Text] [Related]

  • 5. Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.
    Mukherjee A, Lodha R, Kabra SK.
    Expert Opin Pharmacother; 2017 Oct 25; 18(15):1595-1606. PubMed ID: 28847228
    [Abstract] [Full Text] [Related]

  • 6. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U, Huerga H, Khan AJ, Mitnick CD, Hewison C, Varaine F, Bastard M, Rich M, Franke MF, Atwood S, Khan PY, Seung KJ.
    BMC Infect Dis; 2019 Aug 20; 19(1):733. PubMed ID: 31429722
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
    Sotgiu G, Tiberi S, Centis R, D'Ambrosio L, Fuentes Z, Zumla A, Migliori GB.
    Int J Infect Dis; 2017 Mar 20; 56():190-193. PubMed ID: 27816662
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E.
    Appl Health Econ Health Policy; 2018 Feb 20; 16(1):43-54. PubMed ID: 28980217
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
    Gao M, Gao J, Xie L, Wu G, Chen W, Chen Y, Pei Y, Li G, Liu Y, Shu W, Fan L, Wu Q, Du J, Chen X, Tang P, Xiong Y, Li M, Cai Q, Jin L, Mei Z, Pang Y, Li L.
    Clin Microbiol Infect; 2021 Apr 20; 27(4):597-602. PubMed ID: 32553880
    [Abstract] [Full Text] [Related]

  • 17. Treatment outcomes of multidrug resistant tuberculosis (MDR TB) treated with bedaquiline under programmatic management of drug resistant tuberculosis at a tertiary care hospital in Punjab, India.
    Kumari DS, Gupta DA, Chopra DV, Kaur DS.
    Indian J Tuberc; 2024 Apr 20; 71 Suppl 1():S67-S71. PubMed ID: 39067958
    [Abstract] [Full Text] [Related]

  • 18. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B, TMC207-C209 Study Group.
    Eur Respir J; 2016 Feb 20; 47(2):564-74. PubMed ID: 26647431
    [Abstract] [Full Text] [Related]

  • 19. Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India.
    Mehra M, Kambili C, Potluri R, Rhines A, Singh V, Thomas A.
    Int J Tuberc Lung Dis; 2017 Aug 01; 21(8):902-909. PubMed ID: 28786799
    [Abstract] [Full Text] [Related]

  • 20. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.
    Gao J, Gao M, Du J, Pang Y, Mao G, Lounis N, Bakare N, Jiang Y, Zhan Y, Liu Y, Li L, Trial Team.
    Trials; 2024 Apr 01; 25(1):227. PubMed ID: 38561815
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.